Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A descriptive comparative analysis of guideline recommendations, utilization patterns, and research directions without primary efficacy or safety outcome data; provides context on current practice but no new clinical evidence.
A single case report with serial molecular profiling showing clonal evolution under treatment; descriptive and hypothesis-generating but lacking comparative data, control arm, or generalizable evidence of clinical benefit.
Real-world retrospective pharmacy data on persistence and adherence without clinical outcomes, efficacy comparison, or prospective validation; describes treatment patterns rather than clinical benefit or harm.
Preclinical discovery study using virtual screening and in vitro/xenograft models without clinical data; identifies a candidate compound but requires clinical validation.
A single case report with a favorable outcome raises a mechanistic question about drug combination efficacy but provides no comparative evidence, control group, or generalizable data to support clinical practice change.
A critical synthesis and clinical framework addressing heterogeneous stage III NSCLC management in the perioperative immunotherapy era, integrating recent phase III trial evidence with expert consensus on risk-adapted strategies.
Systematic review of economic evidence synthesizing 18 model-based evaluations to inform policy on NGS adoption in NSCLC, with contextual conclusions about cost-effectiveness variability rather than a single definitive clinical or economic finding.
Multi-scale computational prediction of a candidate mutp53-FOXP3 interaction mechanism, supported by associational survival data and in silico modelling but lacking experimental validation of physical sequestration or functional causality.